Citius Pharmaceuticals Inc (CTXR)

$0.60 +0.00 (0.07%)
Market Cap 16.48M
Revenue (ttm) 0.00
Net Income (ttm) -37.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 160,600
Avg Vol 566,752
Day's Range N/A - N/A
Shares Out 27.45M
Stochastic %K 21%
Beta 1.03
Analysts Sell
Price Target $4.00

Company Profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic reli...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 967 6677
Address:
11 Commerce Drive, First Floor, Cranford, United States
yellowjacker
yellowjacker Aug. 21 at 9:23 PM
$CTXR Not much of reaction in after hours trading, but Monday morning the shorts could be looking to cover.
0 · Reply
TwongStocks
TwongStocks Aug. 21 at 8:43 PM
$CTXR Compliance deadline extended to Feb 8, 2027 https://www.sec.gov/Archives/edgar/data/1506251/000121390026092604/ea0302856-8k_citius.htm NOTE: Due to changes to NASDAQ rules 5815 & 5810, CTXR must regain compliance by the 2nd deadline to remain listed on NASDAQ. Failure to regain compliance with the bid price rule before Feb 8 will result in a delisting & suspension of trading. CTXR will not be allowed to stay on NASDAQ, even with an appeal.
0 · Reply
focafoca99
focafoca99 Aug. 21 at 8:29 PM
$CTXR extends its Nasdaq compliance deadline, receiving an extension to Feb 8, 2027 to meet the $1.00 bid price rule. https://www.rapidticker.com/news/ctxr-sec-filing-8960c8
0 · Reply
JackCampbell
JackCampbell Aug. 20 at 10:57 AM
$CTXR Institutional Shares (Long): 1,667,045 - 6.07% (ex 13D/G) - change of 0.55MM shares +49.11% MRQ!!! 2026-08-14 13F Jane Street Group, Llc increased their stake to 122,837 shrs (+445.38%) recently!
0 · Reply
KryptonianTrader
KryptonianTrader Aug. 19 at 8:56 PM
$CTXR RISE SHE WILL.. Patience young apprentice....
1 · Reply
Spicy_Weeklies
Spicy_Weeklies Aug. 19 at 4:30 PM
$CTXR Swung from $0.58 to $0.61.
1 · Reply
Zephix
Zephix Aug. 19 at 3:25 PM
$CTXR Curling up💪🏻
1 · Reply
TwongStocks
TwongStocks Aug. 19 at 3:05 PM
$CTXR Paid promo driving volume higher today. https://bullseyealerts.com/ctxr-18/
4 · Reply
donein12
donein12 Aug. 19 at 3:01 PM
$CTXR There is an awful lot of volume at this time of the day. There are still 5 hours of trading left.
1 · Reply
JackCampbell
JackCampbell Aug. 19 at 2:10 PM
$CTXR this was the last setback as EVERSANA team took over the sales part on 01.08.26 already! Next qtr will be very interesting....mark this post!
1 · Reply
Latest News on CTXR
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Aug 14, 2026, 4:30 PM EDT - 9 days ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

CTOR

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Aug 14, 2026, 4:30 PM EDT - 9 days ago

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

CTOR

Citius Pharmaceuticals Quarterly report: Q3 2026

Aug 14, 2026, 7:00 AM EDT - 9 days ago

Citius Pharmaceuticals Quarterly report: Q3 2026

Citius Pharmaceuticals Earnings release: Q3 2026

Aug 14, 2026, 7:00 AM EDT - 9 days ago

Citius Pharmaceuticals Earnings release: Q3 2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Aug 12, 2026, 8:00 AM EDT - 11 days ago

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

CTOR

Citius Oncology reports availability of Lymphir in institutions grew 78% in Q3

2026-08-05T13:47:34.000Z - 18 days ago

Citius Oncology reports availability of Lymphir in institutions grew 78% in Q3

CTOR

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Aug 5, 2026, 9:17 AM EDT - 18 days ago

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

CTOR

Citius Oncology provides update on commercial launch of Lymphir

2026-07-21T13:25:39.000Z - 4 weeks ago

Citius Oncology provides update on commercial launch of Lymphir

CTOR

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Jul 21, 2026, 9:17 AM EDT - 4 weeks ago

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

CTOR

Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO

2026-06-01T12:16:52.000Z - 2 months ago

Citius Oncology highlights Phase 1 data evaluating Lymphir at ASCO

CTOR

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

CTOR

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

May 26, 2026, 8:00 AM EDT - 3 months ago

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

CTOR

Citius Pharmaceuticals files to sell 5.43M shares of common stock for holders

2026-05-22T21:05:10.000Z - 3 months ago

Citius Pharmaceuticals files to sell 5.43M shares of common stock for holders

Citius Pharmaceuticals Registration statement: Registration filing

May 22, 2026, 8:00 AM EDT - 3 months ago

Citius Pharmaceuticals Registration statement: Registration filing

Citius Pharmaceuticals assumed with a Buy at H.C. Wainwright

2026-05-18T13:00:56.000Z - 3 months ago

Citius Pharmaceuticals assumed with a Buy at H.C. Wainwright

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

May 15, 2026, 4:30 PM EDT - 3 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

CTOR

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

May 15, 2026, 4:30 PM EDT - 3 months ago

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

CTOR

Citius Pharmaceuticals Quarterly report: Q2 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Citius Pharmaceuticals Quarterly report: Q2 2026

Citius Pharmaceuticals Earnings release: Q2 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Citius Pharmaceuticals Earnings release: Q2 2026

Citius Oncology announces initial shipment of LYMPHIR to Europe

2026-04-29T14:53:58.000Z - 4 months ago

Citius Oncology announces initial shipment of LYMPHIR to Europe

CTOR

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

CTOR

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Apr 24, 2026, 4:30 PM EDT - 4 months ago

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals announces $5M registered direct offering priced ATM

2026-04-24T12:14:18.000Z - 4 months ago

Citius Pharmaceuticals announces $5M registered direct offering priced ATM

Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

Mar 31, 2026, 9:11 AM EDT - 5 months ago

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

CTOR

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

CTOR

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

Mar 10, 2026, 8:47 AM EDT - 5 months ago

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

CTOR

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

Mar 4, 2026, 9:15 AM EST - 6 months ago

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

CTOR

Citius Pharmaceuticals receives $3.8M through NJEDA program

2026-02-24T13:06:48.000Z - 6 months ago

Citius Pharmaceuticals receives $3.8M through NJEDA program

Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program

Feb 24, 2026, 8:00 AM EST - 6 months ago

Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program

Citius Pharmaceuticals Proxy statement: Proxy Filing

Feb 24, 2026, 7:00 AM EST - 6 months ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Citius Pharmaceuticals Proxy statement: Proxy Filing

Feb 24, 2026, 7:00 AM EST - 6 months ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir

2026-02-13T13:11:11.000Z - 6 months ago

Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir

CTOR

Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year

2026-02-13T13:10:44.000Z - 6 months ago

Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year

CTOR

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Feb 13, 2026, 8:00 AM EST - 6 months ago

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTOR

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Feb 13, 2026, 8:00 AM EST - 6 months ago

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTOR

Citius Pharmaceuticals Earnings release: Q1 2026

Feb 13, 2026, 7:00 AM EST - 6 months ago

Citius Pharmaceuticals Earnings release: Q1 2026

Citius Pharmaceuticals Quarterly report: Q1 2026

Feb 13, 2026, 7:00 AM EST - 6 months ago

Citius Pharmaceuticals Quarterly report: Q1 2026

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

Feb 11, 2026, 8:00 AM EST - 6 months ago

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

CTOR

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Dec 23, 2025, 4:30 PM EST - 8 months ago

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTOR

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Dec 23, 2025, 4:30 PM EST - 8 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTOR

Citius Pharmaceuticals Earnings release: Q4 2025

Dec 23, 2025, 7:00 AM EST - 8 months ago

Citius Pharmaceuticals Earnings release: Q4 2025

Citius Pharmaceuticals Annual report: Q4 2025

Dec 23, 2025, 7:00 AM EST - 8 months ago

Citius Pharmaceuticals Annual report: Q4 2025

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 10, 2025, 4:30 PM EST - 9 months ago

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTOR

Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering

2025-12-09T13:35:42.000Z - 9 months ago

Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering

CTOR

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2025, 8:30 AM EST - 9 months ago

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTOR

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Dec 4, 2025, 8:37 AM EST - 9 months ago

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

CTOR

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

Dec 1, 2025, 12:00 PM EST - 9 months ago

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

CTOR

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

Nov 25, 2025, 8:00 AM EST - 9 months ago

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

CTOR

Citius Oncology to advance launch of Lymphir with Verix AI integration

2025-11-21T13:45:33.000Z - 9 months ago

Citius Oncology to advance launch of Lymphir with Verix AI integration

CTOR

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

Nov 21, 2025, 8:37 AM EST - 9 months ago

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

CTOR

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 21, 2025, 4:30 PM EDT - 10 months ago

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals announces $6M registered direct offering priced ATM

2025-10-21T12:05:27.000Z - 10 months ago

Citius Pharmaceuticals announces $6M registered direct offering priced ATM

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 21, 2025, 8:00 AM EDT - 10 months ago

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Citius Oncology announces distribution agreement with McKesson

2025-10-20T12:40:10.000Z - 10 months ago

Citius Oncology announces distribution agreement with McKesson

CTOR MCK

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Oct 17, 2025, 5:00 PM EDT - 11 months ago

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTOR

Citius Oncology signs exclusive commercialization agreement with EVERSANA

2025-10-16T12:50:19.000Z - 11 months ago

Citius Oncology signs exclusive commercialization agreement with EVERSANA

CTOR

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Oct 16, 2025, 8:47 AM EDT - 11 months ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

CTOR

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Sep 10, 2025, 4:30 PM EDT - 1 year ago

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTOR

Citius Oncology announces pricing of $9M registered direct offering

2025-09-09T12:38:06.000Z - 1 year ago

Citius Oncology announces pricing of $9M registered direct offering

CTOR

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Sep 9, 2025, 8:30 AM EDT - 1 year ago

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTOR

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

Aug 22, 2025, 8:47 AM EDT - 1 year ago

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

CTOR

Citius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last year

2025-08-12T20:36:02.000Z - 1 year ago

Citius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last year

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals Earnings release: Q3 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Citius Pharmaceuticals Earnings release: Q3 2025

Citius Pharmaceuticals Quarterly report: Q3 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Citius Pharmaceuticals Quarterly report: Q3 2025

Citius Oncology Announces Closing of $9.0 Million Public Offering

Jul 17, 2025, 4:30 PM EDT - 1 year ago

Citius Oncology Announces Closing of $9.0 Million Public Offering

CTOR

Citius Oncology Announces Pricing of $9.0 Million Public Offering

Jul 16, 2025, 9:15 AM EDT - 1 year ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering

CTOR

Citius Oncology signs distribution agreement for Lymphir with Cencora

2025-07-15T12:49:58.000Z - 1 year ago

Citius Oncology signs distribution agreement for Lymphir with Cencora

CTOR

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Jul 15, 2025, 8:32 AM EDT - 1 year ago

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

CTOR

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 8, 2025, 8:34 AM EDT - 1 year ago

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Citius Oncology expects commercial launch of Lymphir in second half of 2025

2025-06-17T12:16:30.000Z - 1 year ago

Citius Oncology expects commercial launch of Lymphir in second half of 2025

CTOR

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

Jun 17, 2025, 8:08 AM EDT - 1 year ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTOR

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Jun 12, 2025, 8:35 AM EDT - 1 year ago

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Jun 10, 2025, 7:00 AM EDT - 1 year ago

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Citius Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 4:30 PM EDT - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals Earnings release: Q2 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Citius Pharmaceuticals Earnings release: Q2 2025

Citius Pharmaceuticals Quarterly report: Q2 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Citius Pharmaceuticals Quarterly report: Q2 2025

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 5, 2025, 8:37 AM EDT - 1 year ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTOR

Citius Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Citius Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Citius Pharmaceuticals Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Apr 1, 2025, 9:00 AM EDT - 1 year ago

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Feb 14, 2025, 4:30 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTOR

Citius Pharmaceuticals Quarterly report: Q1 2025

Feb 14, 2025, 12:00 AM EST - 1 year ago

Citius Pharmaceuticals Quarterly report: Q1 2025

Citius Pharmaceuticals Earnings release: Q1 2025

Feb 14, 2025, 12:00 AM EST - 1 year ago

Citius Pharmaceuticals Earnings release: Q1 2025

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Feb 6, 2025, 8:55 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTOR

Citius Pharmaceuticals Proxy statement: Proxy Filing

Jan 27, 2025, 7:00 AM EST - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Citius Pharmaceuticals Proxy statement: Proxy Filing

Jan 27, 2025, 7:00 AM EST - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Citius Pharmaceuticals Proxy statement: Proxy Filing

Jan 16, 2025, 7:00 AM EST - 1 year ago

Citius Pharmaceuticals Proxy statement: Proxy Filing

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Jan 8, 2025, 8:00 AM EST - 1 year ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Jan 7, 2025, 8:08 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTOR

yellowjacker
yellowjacker Aug. 21 at 9:23 PM
$CTXR Not much of reaction in after hours trading, but Monday morning the shorts could be looking to cover.
0 · Reply
TwongStocks
TwongStocks Aug. 21 at 8:43 PM
$CTXR Compliance deadline extended to Feb 8, 2027 https://www.sec.gov/Archives/edgar/data/1506251/000121390026092604/ea0302856-8k_citius.htm NOTE: Due to changes to NASDAQ rules 5815 & 5810, CTXR must regain compliance by the 2nd deadline to remain listed on NASDAQ. Failure to regain compliance with the bid price rule before Feb 8 will result in a delisting & suspension of trading. CTXR will not be allowed to stay on NASDAQ, even with an appeal.
0 · Reply
focafoca99
focafoca99 Aug. 21 at 8:29 PM
$CTXR extends its Nasdaq compliance deadline, receiving an extension to Feb 8, 2027 to meet the $1.00 bid price rule. https://www.rapidticker.com/news/ctxr-sec-filing-8960c8
0 · Reply
JackCampbell
JackCampbell Aug. 20 at 10:57 AM
$CTXR Institutional Shares (Long): 1,667,045 - 6.07% (ex 13D/G) - change of 0.55MM shares +49.11% MRQ!!! 2026-08-14 13F Jane Street Group, Llc increased their stake to 122,837 shrs (+445.38%) recently!
0 · Reply
KryptonianTrader
KryptonianTrader Aug. 19 at 8:56 PM
$CTXR RISE SHE WILL.. Patience young apprentice....
1 · Reply
Spicy_Weeklies
Spicy_Weeklies Aug. 19 at 4:30 PM
$CTXR Swung from $0.58 to $0.61.
1 · Reply
Zephix
Zephix Aug. 19 at 3:25 PM
$CTXR Curling up💪🏻
1 · Reply
TwongStocks
TwongStocks Aug. 19 at 3:05 PM
$CTXR Paid promo driving volume higher today. https://bullseyealerts.com/ctxr-18/
4 · Reply
donein12
donein12 Aug. 19 at 3:01 PM
$CTXR There is an awful lot of volume at this time of the day. There are still 5 hours of trading left.
1 · Reply
JackCampbell
JackCampbell Aug. 19 at 2:10 PM
$CTXR this was the last setback as EVERSANA team took over the sales part on 01.08.26 already! Next qtr will be very interesting....mark this post!
1 · Reply
Respectable_Level
Respectable_Level Aug. 19 at 1:53 PM
$CTXR
0 · Reply
RME47pilot
RME47pilot Aug. 19 at 12:40 PM
$CTXR It is a junk stock and a junk company. Has nothing to offer and management of this company is beyond poor. All the company does is paid pump and dumps to dupe investors. Lenny Mazur, continually over promises and under delivers on those promises. Stay clear of this unless you enjoy losing your investments.
0 · Reply
bear_foocker
bear_foocker Aug. 17 at 7:33 PM
$CTXR lyin lenny
0 · Reply
np_stocks
np_stocks Aug. 17 at 6:10 PM
$CTXR 😆 can’t make this shit up. Fake pumps for fake people. One day you’ll learn.
0 · Reply
SweStonk
SweStonk Aug. 17 at 5:52 PM
$CTXR have I ever been wrong here ? Pumps always take this lower than before! Dont say I didnt warn you....
0 · Reply
GTMStox
GTMStox Aug. 17 at 5:37 PM
$CTXR More like Shitius Pharmaceuticals
0 · Reply
RME47pilot
RME47pilot Aug. 17 at 2:07 PM
$CTXR 9 Feb 2026, Citius received NASDAQ notice of non-compliance, with 180 days to get back over $1.00. 7 August should have been 180 days. Hopefully it get's delisted and relegated to the pink sheets to save any future investors from this scam.
2 · Reply
RME47pilot
RME47pilot Aug. 17 at 2:03 PM
$CTXR Has this company been relegated to the pink sheets yet?
0 · Reply
900fix
900fix Aug. 17 at 1:58 PM
$CTXR Lenny did it again. Pump n Dump. Now down 24%. Maxim and Lenny are in bed together. Their PT's are a sham. Pie in the sky to get you believing. Lenny is nothing more than a scamster.
1 · Reply
RME47pilot
RME47pilot Aug. 17 at 1:53 PM
$CTXR Junk company and junk stock. Do not waste your money to support Lenny's lies and over promises .
0 · Reply
Tadeo17
Tadeo17 Aug. 17 at 1:36 PM
$CTXR can’t believe i bought it!!!!
1 · Reply
GTMStox
GTMStox Aug. 17 at 1:22 PM
$CTXR Revenue forecasts missed by 70%!...Holy hell!
2 · Reply